8. !. &&, 0/!0;!Z@;43,@;!50>! 4@;40;3/73,@;>!50!890!7

!. E. , !. 8. , and 0. !. >@, >3@-/7??0!/0A/:>0;37;3!60!;@?D/0!50!;@.E07.B!47>!50!8CR!/7AA@/3:>!K!67!A@A.673,@;! 3@3760!0;!Q7.30!03!G7>>0, !X7, vol.37355305555455, issue.157777, pp.0-7

!. Z@, &!1!M7AA@/3!5

!. !. 30>3-!-507, 6. !. A@>>, and !. $. L7d607, 7ZZ0437;3!60!-H;0!8\Q=!==================================================================! )'! L7D607.!*!1!VB0?A60!50!/:-,?0!K!&(%?-!50!890!03!&%%f476gf-!A@, @;>!>7;-.,;0>!50!890!57;>!60>!8CR!467>>,[.0>!=======================! *)!, p.73

!. Z@, O506K!50!&%!?-g56!A@./!60>!&%!A73,0;3>!7330,;3>! 5W!QI8J!0;!Z@, 50>!, vol.434037437, issue.7

P. Pour-la, Phe diminuent rapidement de l'année 0 à l'année 1 d'un facteur de 1,5. Puis, à partir de la 3 ème année (année 2), les taux ne cessent d'augmenter pour atteindre 50% d'échec entre l'année 6 et 7 (soit 1 prélèvement sur 2 supérieur aux normes) De plus, il est important de noter qu'un taux très élevé de 64, 19% de concentrations en Phe supérieures à 5 mg/dl est observé lors de la dernière année

C. Enfants-suivis-au and . De-rouen, Sur les 10 patients atteints d'HMP, aucun n'est encore assez âgé pour pouvoir inclure la 10 ème année (année 9) dans l'étude

H. Bioscience, « Analyseur d'amino-acide -Biochrom 30+ -Harvard Bioscience, Inc. -Vidéos ». Consulté le septembre 20, 2015.

J. E. Antisdel and J. C. Et-chrisler, Comparison of Eating Attitudes and Behaviors Among Adolescent and Young Women with Type 1 Diabetes Mellitus and Phenylketonuria, Journal of Developmental & Behavioral Pediatrics, vol.21, issue.2, pp.81-86, 2000.
DOI : 10.1097/00004703-200004000-00001

A. Belanger-quitana, A. Burlina, C. O. Harding, and A. Et-muntau, Up to date knowledge on different treatment strategies for phenylketonuria, Molecular Genetics and Metabolism, vol.104, pp.19-25, 2011.
DOI : 10.1016/j.ymgme.2011.08.009

L. M. Belloso and M. H. Et-lowitt, Cutaneous findings in a 51-year-old man with phenylketonuria, Journal of the American Academy of Dermatology, vol.49, issue.2, pp.190-92, 2003.
DOI : 10.1067/mjd.2003.261

D. Bilder, B. Burton, H. Coon, L. Leviton, J. Ashworth et al., Psychiatric symptoms in adults with phenylketonuria, Psychiatric symptoms in adults with phenylketonuria, pp.155-60, 2013.
DOI : 10.1016/j.ymgme.2012.12.006

N. Blau, Defining tetrahydrobiopterin (BH4)-responsiveness in PKU, Journal of Inherited Metabolic Disease, vol.29, issue.1, pp.2-3, 2008.
DOI : 10.1007/s10545-007-9979-1

N. Blau and H. Et-erlandsen, The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency, Molecular Genetics and Metabolism, vol.82, issue.2, pp.101-112, 2004.
DOI : 10.1016/j.ymgme.2004.03.006

N. Blau and B. Et-fiege, « Assessment of tetrahydrobioptérine (BH4) responsiveness in phenylketonuria, J.Pedriatr, vol.150, pp.627-657, 2007.

N. Blau, F. Van-spronsen, L. Et, and H. Levy, Phenylketonuria, The Lancet, vol.376, issue.9750, pp.1417-1444, 2010.
DOI : 10.1016/S0140-6736(10)60961-0

A. Bone, K. Kuehl, A. Et-angelino, and A. , A Neuropsychiatric Perspective of Phenylketonuria I: Overview of Phenylketonuria and Its Neuropsychiatric Sequelae, Psychosomatics, vol.53, issue.6, pp.517-540
DOI : 10.1016/j.psym.2012.04.010

A. Boneh, D. E. Francis, M. Humphrey, H. J. Upton, and H. I. Et-peters, Three-year audit of the hyperphenylalaninaemia/phenylketonuria spectrum in Victoria, Journal of Paediatrics and Child Health, vol.112, issue.9, pp.496-98, 2006.
DOI : 10.1016/S0140-6736(02)09334-0

N. C. Bradburn, R. S. Wappner, J. A. Lemons, B. A. Meyer, and R. S. Et-roberts, Lactation and Phenylketonuria, Lactation and phenylketonuria, pp.138-179, 1985.
DOI : 10.1055/s-2007-999931

A. S. Brown, P. M. Fernhoff, S. Waisbren, D. Frazier, R. Singh et al., Barriers to successful dietary control among pregnant women with phenylketonuria, Genetics in Medicine, vol.89, issue.2, pp.84-89, 2002.
DOI : 10.1097/00125817-200203000-00006

B. Burton, L. Leviton, H. Vespa, H. Coon, N. Longo et al., A diversified approach for PKU treatment: Routine screening yields high incidence of psychiatric distress in phenylketonuria clinics, Molecular Genetics and Metabolism, vol.108, issue.1, pp.8-12, 2013.
DOI : 10.1016/j.ymgme.2012.11.003

C. Kathryn, M. Parisi, M. Acosta, P. Berry, G. et al., « Phenylketonuria Scientific Review Conference : State of the science and future research needs, Molecular Genetics and Metabolism, vol.112, issue.2, pp.87-122, 2014.

L. Casey, « Caring for Children with Phenylketonuria », Canadian Family Physician, vol.59, issue.8, pp.837-877, 2013.

D. Cheillan, « Association française pour le dépistage et la prévention des handicaps de l'enfant ». Consulté le août 5, 2015.

M. Cleary, F. Trefz, A. Muntau, F. Feillet, F. Van-spronsen et al., Fluctuations in phenylalanine concentrations in phenylketonuria: A review of possible relationships with outcomes, Molecular Genetics and Metabolism, vol.110, issue.4, pp.418-441, 2013.
DOI : 10.1016/j.ymgme.2013.09.001

M. Cleary, J. H. Walter, J. E. Wraith, F. White, K. Tyler et al., Magnetic resonance imaging in phenylketonuria: Reversal of cerebral white matter change, The Journal of Pediatrics, vol.127, issue.2, pp.127-251, 1995.
DOI : 10.1016/S0022-3476(95)70303-9

J. Dhondt, « Deficit en dihydroptétidine-réductase ». Consulté le août 7, 2015.

Z. Ding, C. O. Harding, A. Rebuffat, L. Elzaouk, J. A. Wolff et al., Correction of Murine PKU Following AAV-mediated Intramuscular Expression of a Complete Phenylalanine Hydroxylating System, Molecular Therapy, vol.16, issue.4, pp.673-81, 2008.
DOI : 10.1038/mt.2008.17

S. Dobrowolski, K. Borski, C. C. Ellingson, R. Koch, H. Levy et al., A limited spectrum of phenylalanine hydroxylase mutations is observed in phenylketonuria patients in western Poland and implications for treatment with 6R tetrahydrobiopterin, Journal of Human Genetics, vol.123, issue.6, pp.335-374, 2009.
DOI : 10.1007/s10545-006-0096-3

G. Durand and J. L. Et-beaudeux, Biochimie médicale : Marqueurs actuels et perspectives, 2011.

R. Durand, Une nouvelle classe de prot??ines : les mol??cules chaperonnes, m??decine/sciences, vol.7, issue.5, pp.496-99, 1991.
DOI : 10.4267/10608/4391

M. Frederico, Phosphorylation and Mutation of Ser16 in Human Phenylalanine Hydroxylase, The journal of Biological Chemistry, vol.277, pp.40937-40980, 2002.

R. Gassio, R. Artuch, M. A. Vilaseca, E. Fuste, R. Colome et al., Cognitive functions and the antioxidant system in phenylketonuric patients., Cognitive functions and the antioxidant system in phenylketonuric patients, pp.426-457, 2008.
DOI : 10.1037/0894-4105.22.4.426

R. Gassio, J. Campistol, M. A. Vilaseca, N. Lambruschini, F. J. Cambra et al., Do adult patients with phenylketonuria improve their quality of life after introduction/resumption of a phenylalanine-restricted diet?, Acta Paediatrica, vol.51, issue.Suppl 2, pp.1474-78, 2003.
DOI : 10.1111/j.1651-2227.2003.tb00834.x

F. A. Greco, « Plasma amino acids : MedlinePlus Medical Encyclopedia ». Plasma amino acids, 2015.

G. Travert, « Dépistage néonatal -EM|Premium, 2013.

F. Guttler, E. S. Olesen, and E. Et-wamberg, « Diurnal variations of serum phenylalanine in phénylketonuric childrenon low phenylalanine diet. » Am, J. Clin. Nutr, vol.22, pp.1568-70, 1969.

V. Guzzetta, G. Bonapace, I. Dianzani, G. Parenti, M. Lecora et al., « Phenylketonuria in Italy : distinct distribution pattern of three mutations of the phenylalanine hydroxylase gene, Journal of Inherited Metabolic Disease, vol.20, issue.5, pp.619-643, 1997.
DOI : 10.1023/A:1005315106604

C. O. Harding, Progress toward cell-directed therapy for phenylketonuria, Clinical Genetics, vol.317, issue.Suppl. 1, pp.97-104, 2008.
DOI : 10.1111/j.1399-0004.2008.01027.x

«. Has:-haute-autorité-de-santé, Consulté le août 5, 2015.

«. Has-haute-autorité-de-santé, Consulté le août 5, 2015.

C. Heintz, R. G. Cotton, and N. Et-blau, Tetrahydrobiopterin, its Mode of Action on Phenylalanine Hydroxylase, and Importance of Genotypes for Pharmacological Therapy of Phenylketonuria, Human Mutation, vol.29, issue.1, pp.927-963, 2013.
DOI : 10.1002/humu.22320

J. Hennermann, S. Roloff, C. Gebauer, B. Vetter, V. Arnim-baas et al., Long-term treatment with tetrahydrobiopterin in phenylketonuria: Treatment strategies and prediction of long-term responders, Molecular Genetics and Metabolism, vol.107, issue.3, pp.294-301, 2012.
DOI : 10.1016/j.ymgme.2012.09.021

M. A. Hilton, J. N. Sharpe, L. G. Hicks, and B. F. Et-andrews, A simple method for detection of heterozygous carriers of the gene for classic phenylketonuria, The Journal of Pediatrics, vol.109, issue.4, pp.601-605, 1986.
DOI : 10.1016/S0022-3476(86)80220-7

R. Jahja, S. Huijbregts, L. De-sonneville, J. Van-der-meere, and F. Et-van-spronsen, Neurocognitive Evidence for Revision of Treatment Targets and Guidelines for Phenylketonuria, The Journal of Pediatrics, vol.164, issue.4, pp.895-99, 2014.
DOI : 10.1016/j.jpeds.2013.12.015

J. Kasnauskiene, S. Giannattasio, P. Lattanzio, L. Cimbalistiene, and V. Et-kucinskas, The molecular basis of phenylketonuria in Lithuania, Human Mutation, vol.21, issue.4, p.398, 2003.
DOI : 10.1002/humu.9113

D. O. Kennedy and C. F. Haskell, Vitamins and Cognition, Drugs, vol.68, issue.2, pp.1957-71, 2011.
DOI : 10.2165/11594130-000000000-00000

N. M. Kilpatrick, H. Awang, B. Wilcken, and J. Et-christodoulou, « The implication of phenylketonuria on oral health, » Pediatr. Dent, vol.21, pp.433-470, 1999.

S. Kure, K. Sato, K. Fujii, Y. Aoki, Y. Suzuki et al., Wild-type phenylalanine hydroxylase activity is enhanced by tetrahydrobiopterin supplementation in vivo: an implication for therapeutic basis of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency, Molecular Genetics and Metabolism, vol.83, issue.1-2, pp.150-56, 2004.
DOI : 10.1016/j.ymgme.2004.06.016

E. Laconi and S. Et-laconi, Principles of hepatocyte repopulation, Seminars in Cell & Developmental Biology, vol.13, issue.6, pp.433-471, 2002.
DOI : 10.1016/S1084952102001313

S. Lage, M. Bueno, F. Andrade, J. A. Prieto, C. Delgado et al., Fatty acid profile in patients with phenylketonuria and its relationship with bone mineral density, Journal of Inherited Metabolic Disease, vol.88, issue.Suppl 1, pp.363-71, 2010.
DOI : 10.1007/s10545-010-9189-0

W. D. Lehmann, R. Fischer, H. C. Heinrich, P. Clemens, and R. Gruttner, Metabolic conversion of l-[U-14C]phenylalanine to respiratory 14CO2 in healthy subjects, phenylketonuria heterozygotes and classic phenylketonurics, Clinica Chimica Acta, vol.157, issue.3, pp.253-66, 1986.
DOI : 10.1016/0009-8981(86)90301-3

A. Lipson, B. Beuhler, J. Bartley, and . Et, Maternal hyperphenylalaninemia fetal effects, Maternal hyperphenylalaninemia fetal effects, pp.216-236, 1984.
DOI : 10.1016/S0022-3476(84)80995-6

S. Lohner, K. Fekete, and T. Et-decsi, Lower n-3 long-chain polyunsaturated fatty acid values in patients with phenylketonuria: a systematic review and meta-analysis, Nutrition Research, vol.33, issue.7, pp.513-533, 2013.
DOI : 10.1016/j.nutres.2013.05.003

C. C. Mabry, J. C. Denniston, T. L. Nelson, and C. D. Et-son, Maternal Phenylketonuria, New England Journal of Medicine, vol.269, issue.26, pp.1404-1412, 1967.
DOI : 10.1056/NEJM196312262692604

A. Macdonald, A. Chakrapani, C. Hendriksz, A. Daly, P. Davies et al., Protein substitute dosage in PKU: how much do young patients need?, Archives of Disease in Childhood, vol.91, issue.7, pp.588-93, 2006.
DOI : 10.1136/adc.2005.084285

A. Macdonald, B. Cochrane, H. Wopereis, and N. Et-loveridge, Specific prebiotics in a formula for infants with Phenylketonuria, Molecular Genetics and Metabolism, vol.104, pp.55-59, 2011.
DOI : 10.1016/j.ymgme.2011.09.015

A. Macdonald, S. Evans, B. Cochrane, and J. Et-wildgoose, Weaning infants with phenylketonuria: a review, Journal of Human Nutrition and Dietetics, vol.13, issue.Suppl., pp.103-113, 2012.
DOI : 10.1111/j.1365-277X.2011.01199.x

E. L. Macleod and D. M. Et-ney, Nutritional Management of Phenylketonuria, Annales Nestl?? (English ed.), vol.68, issue.2, pp.58-69
DOI : 10.1159/000312813

F. Maillot, M. Lilburn, J. Baudin, D. W. Morley, and P. J. Et-lee, « Factors influencing outcommes in theoffspring of mothers with phenylketonuria during pregnancy: the importance of variation in maternal blood phenylalanine, Am. J. Clin. Nutr, vol.88, pp.700-705, 2008.

K. Matalon, P. Acosta, and C. Et-azen, Role of nutrition in pregnancy with phenylketonuria and birth defects », Pediatrics, vol.112, pp.1534-1570, 2003.

R. Matalon, K. Michals-matalon, G. Bhatia, A. B. Burlina, A. P. Burlina et al., Double blind placebo control trial of large neutral amino acids in treatment of PKU: Effect on blood phenylalanine, Journal of Inherited Metabolic Disease, vol.25, issue.(Supplement 1), pp.153-58, 2008.
DOI : 10.1007/s10545-007-0556-4

A. Miras, M. D. Boveda, M. R. Leis, A. Mera, L. J. Aldamiz-echevarria et al., Risk factors for developing mineral bone disease in phenylketonuric patients, Molecular Genetics and Metabolism, vol.108, issue.3, pp.149-54, 2013.
DOI : 10.1016/j.ymgme.2012.12.008

J. J. Mitchell, Y. J. Trakadis, and C. R. Et-scriver, Phenylalanine hydroxylase deficiency, Phenylalanine hydroxylase deficiency, pp.697-707, 2011.
DOI : 10.1097/GIM.0b013e3182141b48

A. M. Molloy, P. N. Kirke, L. C. Brody, J. M. Scott, and J. L. Et-mills, Deficiencies During Pregnancy on Fetal, Infant, and Child Development, Food and Nutrition Bulletin, vol.37, issue.5, pp.101-112, 2008.
DOI : 10.1177/15648265080292S114

D. M. Ney, A. K. Gleason, S. C. Van-calcar, E. L. Macleod, M. R. Etzel et al., Nutritional management of PKU with glycomacropeptide from cheese whey, Journal of Inherited Metabolic Disease, vol.43, issue.Supplement 2, pp.32-39, 2009.
DOI : 10.1007/s10545-008-0952-4

D. M. Ney, A. K. Hull, S. C. Van-calcar, X. Liu, and M. R. Et-etzel, « Dietary glycomacropeptide supports growth and reduces the concentrations of phenylalanine in plasma and brain in murine model of phenylketonuria, 2008.

J. B. Nielsen, K. E. Nielsen, and F. Et-guttler, Tetrahydrobiopterin responsiveness after extended loading test of 12 Danish PKU patients with the Y414C mutation, Journal of Inherited Metabolic Disease, vol.347, issue.1, pp.9-16, 2010.
DOI : 10.1007/s10545-009-9002-0

M. P. Nova, M. Kaufman, and A. Et-halperin, Scleroderma-like skin indurations in a child with phenylketonuria: A clinicopathologic correlation and review of the literature, Journal of the American Academy of Dermatology, vol.26, issue.2, pp.329-362, 1992.
DOI : 10.1016/0190-9622(92)70048-K

E. Passarge, Atlas de poche de génétique. Médecine-Science, 2008.

J. Pietz, R. Kreis, A. Rupp, E. Mayatepek, D. Rating et al., Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria, Journal of Clinical Investigation, vol.103, issue.8, 1999.
DOI : 10.1172/JCI5017

N. Porchet, « Les interactions métabolisme/signalisation génétique, au travers d'exemple -». https, 2011.

F. Porta, A. Mussa, A. Zanin, N. A. Greggio, A. Burlina et al., Impact of Metabolic Control on Bone Quality in Phenylketonuria and Mild Hyperphenylalaninemia, Journal of Pediatric Gastroenterology and Nutrition, vol.52, issue.3, pp.345-50, 2011.
DOI : 10.1097/MPG.0b013e3182093b32

J. Quevauvilliers, A. Somogyi, and A. Et-fingerhut, Dictionnaire médical. 6ème éd, 2009.

C. N. Sarkissian, A. Gamez, L. Wang, M. Charbonneau, P. Fitzpatrick et al., Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria, Proceedings of the National Academy of Sciences, vol.105, issue.52, pp.20894-99, 2008.
DOI : 10.1073/pnas.0808421105

I. Saruggia and J. Et-wenz, « Nutricia livre de recettes.pdf ». Consulté le octobre 9, 2015.

R. H. Singh and M. E. Et-quirk, Using change in plasma phenylalanine concentrations and ability to liberalize diet to classify responsiveness to tetrahydrobiopterin therapy in patients with phenylketonuria, Molecular Genetics and Metabolism, vol.104, issue.4, pp.485-91, 2011.
DOI : 10.1016/j.ymgme.2011.09.009

P. D. Stenson, « HGMD® mutation result ». Consulté le septembre 23, 2015.

R. Nowak, E. Assoun, M. Mention, K. Cano, A. Fouilhoux et al., « Maternal phenylketonuria : low phenylalaninemia might increase the risk of intra uterine growth retardation, J. Inherit. Metab. Dis, vol.35, pp.993-99, 2012.

J. Underhaug, O. Aubi, and A. Et-martinez, Phenylalanine Hydroxylase Misfolding and Pharmacological Chaperones, Phenylalanine Hydroxylase Misfolding and Pharmacological Chaperones, pp.2534-2579, 2012.
DOI : 10.2174/1568026611212220008

P. Vajro, P. Strisciuglio, D. Houssin, G. Huault, J. Laurent et al., Correction of Phenylketonuria after Liver Transplantation in a Child with Cirrhosis, New England Journal of Medicine, vol.329, issue.5, p.363, 1993.
DOI : 10.1056/NEJM199307293290517

M. Van-rijn, M. Hoeksma, P. J. Sauer, P. Moddeman, D. J. Rejingoud et al., Diurnal variations in blood phenylalanine of PKU infants under different feeding regimes, Diurnal variations in blood phenylalanine of PKU infants under different feeding regimes, pp.68-72, 2011.
DOI : 10.1016/j.ymgme.2011.08.010

F. J. Van-spronsen, M. Hoeksma, and D. J. Et-reijngoud, Brain dysfunction in phenylketonuria: Is phenylalanine toxicity the only possible cause?, Journal of Inherited Metabolic Disease, vol.15, issue.1, pp.46-51, 2009.
DOI : 10.1007/s10545-008-0946-2

F. J. Van-spronsen, M. Van-rijn, T. Van-dijk, G. P. Smit, D. J. Reijngoud et al., « Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting/postprandial) in patients with phenylketonuria : effect of sample timing, Pediatrics, vol.92, pp.570-73, 1993.

F. Van-spronsen, D. Groot, M. J. Hoeksma, M. Rejingoud, D. J. Et-van-rijn et al., Large neutral amino acids in the treatment of PKU: from theory to practice, Journal of Inherited Metabolic Disease, vol.32, issue.Suppl 1, pp.671-76, 2010.
DOI : 10.1007/s10545-010-9216-1

F. Van-spronsen, M. Van-rijn, B. Dorgelo, M. Hoeksma, A. M. Bosch et al., Phenylalanine tolerance can already reliably be assessed at the age of 2??years in patients with PKU, Journal of Inherited Metabolic Disease, vol.16, issue.Supplement 1, pp.27-31, 2009.
DOI : 10.1007/s10545-008-0937-3

H. M. Viecelli, R. P. Harbottle, M. Chuah, T. Vandriessche, C. O. Harding et al., « Liver gene therapy for PKU using naked DNA/minicircle vectors expressing phenylalanine hydroxylase from a synthetic minigene, p.56, 2012.

S. Waisbren, K. Noel, K. Fahrbach, C. Cella, D. Frame et al., Phenylalanine blood levels and clinical outcomes in phenylketonuria: A systematic literature review and meta-analysis, Molecular Genetics and Metabolism, vol.92, issue.1-2, pp.63-70, 2007.
DOI : 10.1016/j.ymgme.2007.05.006

K. Widaman and C. Et-azen, « Relation of prenatal phenylalanine exposure to infant and chilhood cognitive outcomes : results from the International Maternal PKU Collaborative Study, Pediatrics, vol.112, pp.1537-1580, 2003.

S. Yano, K. Moseley, and C. Et-azen, Melatonin and Dopamine as Biomarkers to Optimize Treatment in Phenylketonuria: Effects of Tryptophan and Tyrosine Supplementation, The Journal of Pediatrics, vol.165, issue.1, pp.184-89, 2014.
DOI : 10.1016/j.jpeds.2014.03.061

Z. X. Zhang, J. Ye, W. J. Qiu, L. S. Han, and X. F. Et-gu, « Screening and diagnosis oh tetrahydrobiopterin responsive phenylalanine hydroxylase deficiency with tetrahydrobiopterin loading test, Zhonghua Er Ke Za Zhi, vol.43, pp.335-374, 2005.